
Elusys Delivers Anthrax Countermeasure Order, Gains Funding for Lyophilization Effort
Elusys Therapeutics, Inc. has received payment from the U.S. federal government for completing the second delivery of its medical countermeasure for inhalational anthrax, according to a Jan. 24 statement by the company. [Read more]